--- title: "Aclaris Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285620105.md" datetime: "2026-05-07T21:06:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285620105.md) - [en](https://longbridge.com/en/news/285620105.md) - [zh-HK](https://longbridge.com/zh-HK/news/285620105.md) --- # Aclaris Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M Revenue: As of FY2026 Q1, the actual value is USD 1.996 M, beating the estimate of USD 1.322 M. EPS: As of FY2026 Q1, the actual value is USD -0.15, beating the estimate of USD -0.1578. EBIT: As of FY2026 Q1, the actual value is USD -23.71 M. Aclaris Therapeutics, Inc. operates as one reportable segment focused on immuno-inflammatory diseases, generating revenue through intellectual property licensing and laboratory services . #### Revenue - **Total Revenue**: Increased to $1,996 thousand for the three months ended March 31, 2026, from $1,455 thousand for the same period in 2025 . - **Contract Research Revenue**: Rose to $537 thousand in Q1 2026 from $445 thousand in Q1 2025, driven by higher billed hours, partially offset by a lower average billing rate . - **Licensing Revenue**: Increased to $1,459 thousand in Q1 2026 from $1,010 thousand in Q1 2025, attributed to higher royalties from the Lilly and Sun Pharma license agreements . #### Operational Metrics - **Net Loss**: The net loss was -$19,824 thousand for the three months ended March 31, 2026, compared to -$15,085 thousand for the same period in 2025 . - **Loss from Operations**: Increased to -$22,192 thousand in Q1 2026 from -$18,084 thousand in Q1 2025 . - **Total Costs and Expenses**: Increased to $24,188 thousand in Q1 2026 from $19,539 thousand in Q1 2025 . - **Cost of Revenue**: Decreased to $395 thousand in Q1 2026 from $506 thousand in Q1 2025, primarily due to lower personnel-related costs . - **Research and Development (R&D) Expenses**: Increased to $15,657 thousand in Q1 2026 from $11,584 thousand in Q1 2025 . - **General and Administrative (G&A) Expenses**: Increased to $6,743 thousand in Q1 2026 from $6,139 thousand in Q1 2025 . - **Licensing Expenses**: Increased to $1,393 thousand in Q1 2026 from $1,010 thousand in Q1 2025, due to higher royalties earned under license agreements . - **Revaluation of Contingent Consideration**: Was $0 in Q1 2026, down from $300 thousand in Q1 2025 . - **Other Income**: Total other income was $2,368 thousand in Q1 2026, down from $2,999 thousand in Q1 2025 . - **Interest Income**: Decreased to $1,514 thousand in Q1 2026 from $2,166 thousand in Q1 2025, due to a lower average investment balance and lower interest rates . - **Non-cash Royalty Income**: Remained consistent at $854 thousand in Q1 2026 and $833 thousand in Q1 2025, related to the sale of OLUMIANT® royalty payments . #### Cash Flow - **Net Cash Used in Operating Activities**: Increased to -$18,149 thousand in Q1 2026 from -$13,057 thousand in Q1 2025, primarily due to higher net losses after non-cash adjustments . - **Net Cash Used In Investing Activities**: Changed from a net cash provided of $19,119 thousand in Q1 2025 to a net cash used of -$30,932 thousand in Q1 2026, mainly due to greater purchases of marketable securities and lower proceeds from sales and maturities . - **Net Cash Provided by Financing Activities**: Increased to $57,781 thousand in Q1 2026 from -$275 thousand in Q1 2025, primarily due to proceeds from at-the-market common stock sales . - **Cash and Cash Equivalents**: Ended Q1 2026 at $28,660 thousand, up from $19,960 thousand at December 31, 2025 . #### Unique Metrics - **Accumulated Deficit**: As of March 31, 2026, the accumulated deficit was -$987.6 million . - **Contingent Consideration Liability**: Remained at $11.0 million as of March 31, 2026 and December 31, 2025 . - **Marketable Securities**: Totaled $162.1 million as of March 31, 2026, compared to $131.4 million as of December 31, 2025 . - **Stock-based Compensation Expense**: Totaled $3,198 thousand in Q1 2026, down from $3,535 thousand in Q1 2025 . #### Future Outlook and Strategy Aclaris Therapeutics, Inc. expects to incur significant net losses and operating expenses as it advances its product candidates through development, aiming to finance operations through equity sales, non-dilutive financing, and potential partnerships . The company believes its current cash, cash equivalents, and marketable securities are sufficient to fund operating and capital expenditure requirements for over 12 months from the financial statement issuance date . Key product development timelines include top-line data for Bosakitug in Q4 2026, initiation of a Phase 2b study for ATI-2138 in H2 2026, top-line data for ATI-052 in H2 2026, and an IND filing for ATI-9494 in H2 2026 . ### Related Stocks - [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md) ## Related News & Research - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Sangoma Announces Third Quarter Fiscal 2026 Results | SANG Stock News](https://longbridge.com/en/news/286317217.md) - [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md) - [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md)